Applying its expertise in medicinal and synthetic chemistry, ChemDiv will support Achaogen in identifying and developing novel antibacterial compounds.
Heinz Moser, senior vice president for chemistry at Achaogen, said: “We are pleased to be working with ChemDiv on this important medicinal chemistry effort to optimize SOS pathway inhibitors discovered by Achaogen. These inhibitors could prove to be powerful new tools in the battle against antimicrobial resistance.”